S
616.992
H2cm
1985
c.1

CANCER IN MONTANA

PLEASE RETURN

1979 – 1982

STATE DOCUMENTS COLLECTION

AUG 11 1986

MONTANA STATE LIBRARY
1515 E. 6th AVE.
HELENA, MONTANA 59620

Montana Central Tumor Registry
State Dept. of Health & Environmental Sciences
Cogswell Building
Helena, MT 59620

MONTANA STATE LIBRARY
S 616.992 H2cm 1985 c.1
Cancer in Montana, 1979-1982 /
3 0864 00054180 8

CANCER IN MONTANA

1979 - 1982

MONTANA CENTRAL TUMOR REGISTRY
STATE DEPT. OF HEALTH & ENVIRONMENTAL SCIENCES
COGSWELL BUILDING
HELENA, MT 59620

MONTANA STATE LIBRARY
1515 E. 6th AVE.
HELENA, MONTANA 59620

Published 1985

Carol A. Snyder
Program Manager

86-62

Digitized by the Internet Archive
in 2014

http://archive.org/details/cancerinmontana11985mont

TABLE OF CONTENTS

	Page
INTRODUCTION	1
ADMINISTRATIVE RULES OF MONTANA -- TUMOR REGISTRY	3
ADVISORY BOARD	6
SPECIAL STUDIES	7
DISTRIBUTION OF TEN MOST FREQUENT SITES	9
FIVE MOST COMMON CANCER SITES -- INCIDENCE BY COUNTY	11
DATA AND DEFINITIONS	12
GRAPHICS -- ALL SITES -- 1979-1982	
Total Sites	15
Mouth	16
Pharynx	17
Esophagus	18
Stomach	19
Colon	20
Rectum	21
Pancreas	22
Larynx	23
Lung	24
Acute Leukemia	25
Chronic Leukemia	26
Multiple Myeloma	27
Melanoma Skin	28
Female Breast	29
Cervix In-situ	30
Cervix Uteri	31
Corpus Uteri	32
Ovary-Tube-Ligament	33
Female Genital	34
Prostate	35
Testis	36
Bladder	37
Kidney	38
Brain & Central Nervous System	39
Thyroid	40
Hodgkins Lymphoma	41
Non-Hodgkins Lymphoma	42
Unknown Primary	43

INTRODUCTION

The Mary Swift Tumor Clinic in Butte was one of the first tumor registries in Montana. It was established in the 1950's under the direction of Dr. John Newman and continued operations until November, 1983. The Tumor Clinic's patient registry was later included in the Montana Central Tumor Registry.

In 1970, a central tumor registry was established by the Montana Medical Education and Research Foundation, Mountain States Regional Medical Program; it existed for only 18 months. This activity was phased out after the federal government discontinued regional medical programs.

Five years later, the Montana Foundation for Medical Care attempted to reestablish the tumor registry, which lasted another 18 months. This attempt failed not by choice of the participating hospitals, but because federal funds were once again eliminated. At that time, when the registry was discontinued, there were 33 hospitals participating in the program; however, the collected cancer data were never utilized.

In 1979, the Montana Central Tumor Registry (MCTR) was approved for two years by the legislative session, to be under the direction of the State Department of Health and Environmental Sciences. Although the hospitals were concerned about the possible collapse of funding again, the program won the confidence of a total of 46 hospitals which were anxious to contribute their cancer data in order to provide uniform statewide cancer reporting and a follow-up end result information data system for the use of everyone involved in cancer treatment and prevention -- a goal that had never been achieved from the previous tumor registries.

These 46 hospitals elected either to be visited on a periodic basis by contracted staff from the Montana Foundation for Medical Care, or to maintain their own tumor registry. During this time, detailed cancer data were collected on 2,352 cancer patients diagnosed with cancer in 1979 and 1980.

Due to dedicated professionals and community support, the 1981 legislature passed Senate Bill 37 to continue funding the Montana Central Tumor Registry. Included in the bill was a law mandating cancer as a reportable disease, requiring all hospitals in the state to report their cancer experience.

In 1985, the legislature approved House Bill 113, which provided for cancer reporting by independent clinical laboratories in addition to hospitals. These bills were important in helping the MCTR obtain more complete, reliable statistics and in furthering the objective of a valid population-based cancer registry for the state.

Currently, 66 hospitals, including Veterans' Administration hospitals and cancer treatment centers, are reporting cancer data to the central office in Helena where data are coded for computer entry and controlled for quality.

The primary goals of the Montana Central Tumor Registry are:

1. To facilitate the systematic follow-up of cancer patients at regular intervals in order to help save lives by early detection and treatment of local recurrence, recurrence in regional lymph nodes, solitary distant metastases, and additional primary lesions.

2. To provide meaningful feedback to the medical profession regarding cancer in their practices, hospitals, state and region.

3. To define areas of further research and planning.

4. To determine statistical facts about early diagnosis, treatment and survival in various malignant diseases in order to help evaluate and formulate educational efforts and improve patient care.

The Montana Central Tumor Registry is a member of the Rocky Mountain Cancer Data System (RMCDS) based in Salt Lake City, Utah. Membership in RMCDS has allowed Montana to utilize the central data processing capabilities of this system. As a result, the MCTR distributes monthly and annual reports to all participating hospitals which reflect their cancer patients' experience.

Participation in the regional data system links Montana with a nationwide cancer patient surveillance program which provides vital information for research into the cause, treatment and prevention of cancer.

In addition, follow-up letters are automatically generated by RMCDS for the Central Registry. The follow-up letters help to assure a systematic follow-up of cancer patients via their private physicians. Data from the Records and Statistics Bureau are also used to record death information for patient follow-up.

In 1985, the MCTR is planning to install its own on-line computer. This will allow MCTR staff to directly input, change, update or remove cases on the registry. The Central Registry will continue its membership with RMCDS, but in a slightly different capacity. Although the MCTR will no longer utilize batch system processing through RMCDS, Rocky Mountain will still provide a number of services, including technical assistance, statistical reports, and data back-up.

Hospital registry reference dates vary because some hospitals began abstracting in 1979, some in 1980, etc. Therefore, it has been difficult to produce complete years of cancer data for publication of a statewide cancer report. This report is an effort to present the data collected so far and to illustrate the capabilities of Montana's cancer reporting system.

Sub-Chapter 5
Tumor Registry

16.32.501 REPORTABLE TUMORS (1) The following tumors are designated as reportable:

(a) Malignant neoplasm, with the exception of a basal or squamous carcinoma of the skin;

(b) Skin cancer of the labia, vulva, penis, or scrotum;

(c) Benign tumor of the brain, including a:

(i) meningioma (cerebral meninges)

(ii) pinealoma (pineal gland)

(iii) adenoma (pituitary gland);

(d) Carcinoid tumor, whether malignant, benign, or not otherwise specified (NOS).

(2) A benign tumor other than one of those listed in subsection (1) of this rule may be reported to the department for inclusion in the tumor registry if prior approval has been obtained from the department [Preventive Health Services Bureau, Tumor Registry, Cogswell Building, 1400 Broadway, Helena, MT., 59620; phone: 449-4740].

(3) A tumor which is otherwise reportable, but has been diagnosed and recorded using the words "questionable", "possible", "suggests", or "equivocal", is not considered a reportable tumor.

(4) Whenever records of a patient with a tumor which would be reportable, if confirmed, contain the words "suspect", "probable", "suspicious", "compatible with" or "consistent with" in reference to that tumor, the tumor is considered reportable. (History: Sec. 50-15-706, MCA, IMP, Sec. 50-15-703, MCA, NEW, 1982 MAR p. 391, Eff. 2/26/82.)

16.32.502 REQUIRED RECORDS -- INITIAL ADMISSION AND TREATMENT Whenever a hospital initially provides medical services to any patient relating to a tumor designated as reportable by 16.32.502, it must collect, record, and make available to the department the following information about that patient:

(1) Name and current address of patient

(2) Patient's address at time of diagnosis

(3) Social security number

(4) Name of spouse, if any

(5) Phone number

(6) Race, sex, marital status, religion (optional)

(7) Age at diagnosis; place of birth; and month, day and year of birth

(8) Name, address, and phone number of friend or relative to act as contact, plus relationship of that contact to patient

(9) Date and place of initial diagnosis

(10) Primary site of tumor (paired organ)

(11) Sequence of primary tumors, if more than one

(12) Other primary tumors

(13) Method of confirming diagnosis

(14) Histology, including dates, place, histologic type, and slide number
(15) Summary staging, including whether in situ; localized; regional; distant; or unstaged, with no information
(16) Description of tumor and its spread, if any, including size in centimeters, number of positive nodes, number of nodes examined, and site of distant metastases
(17) Whether AJC or TNM staging is utilized; and if so, the findings of the staging
(18) Cumulative summary of all therapy directed at the subject tumor, including:
(a) date of therapy;
(b) specific type of surgery or radiation therapy, if any; and details of chemical, hormonal, or other kinds of treatment;
(c) if no therapy given, reason for lack of therapy.
(19) Status at time of latest recorded information, i.e., whether alive or dead; tumor in evidence or recurring; or status unknown
(20) If recurrence of tumor, type and distant site of first recurrence.
(21) Names of physicians primarily and secondarily responsible for follow-up.
(22) Date of each follow-up
(23) If patient has died, date of death, place, cause, and whether autopsy performed. (History: Sec. 50-15-706, MCA; IMP, Sec. 50-15-703, MCA; NEW, 1982 MAR p. 391, Eff. 2/26/82.)

16.32.503 REQUIRED RECORDS -- FOLLOW-UP Whenever a patient for whom information has been provided to the tumor registry is admitted to the hospital providing the information on an inpatient or outpatient basis for further treatment related to the tumor for which original registration in the tumor registry was made, the hospital must keep on file the following information:
(1) Patient's name, noting any change from previous records;
(2) Any paired organ involvement, noting sequence;
(3) Subsequent histology, including dates, place, histology type, slide number, and precedure;
(4) Date, type of procedure, and findings of any surgery or other exploratory measure;
(5) Date and type of any administration of radiation;
(6) Date of any administration of hormones, chemotherapy, immunotherapy, or any other kind of treatment;
(7) Date of death and/or last follow-up;
(8) If death has occurred, the place, cause, and whether an autopsy was performed;
(9) If autopsy performed, its findings pertaining to cancer;

(10) Status at time of latest recorded information, i.e., whether alive or dead; tumor in evidence or has recurred; or status is unknown;

(11) If recurrence of tumor, type and distant sites of first recurrence;

(12) Names of those physicians primarily and secondarily responsible for follow-up treatment. (History: Sec. 50-15-706, MCA; IMP, Sec. 50-15-703, MCA; NEW, 1982 MAR p. 391, Eff. 2/26/82.)

ADVISORY BOARD

The Montana Central Tumor Registry Advisory Board was established in 1982 to provide consultation and make recommendations for the program. Some examples of this effort include: providing guidelines for coding of cancer recurrence, encouraging hospitals to accomplish complete reporting, promoting cancer reporting by private clinical laboratories, recommending and approving procedures for lost patient follow-up, supporting legislation concerning cancer reporting laws.

The current Advisory Board Members are listed below:

Stephen Black, D.D.S., P.C.
Bozeman

Neel Hammond, M.D.
Billings

Elmer E. Kobold, M.D.
Billings

Joseph Rizza, M.D.
Helena

Stephen Speckart, M.D.
Missoula

Bernard J. Winter, M.D.
Fort Harrison, Helena

Martin Hamilton, Ph.D.
Montana State University, Bozeman

Mary Kerins, R.R.A.
(Chairperson), Helena

William Leary
Montana Hospital Association, Helena

Martin D. Skinner, M.D.
Helena

E. Stan Wieczorek
American Cancer Society, Billings

David M. Young, D.V.M., Ph.D.
Montana State University, Bozeman

SPECIAL STUDIES

Listed below are requests that the registry has received, requiring the use of our tumor registry data. No personally identified information, either by hospital or patient name, is released to persons or organizations who are not authorized to receive such information.

	STUDY	REQUESTED BY
1.	List of all NRCC patients by county of residence (including Wyoming) and by physicians.	Northern Rockies Regional Cancer Center, Billings
2.	List of patients reported by both St. James Community Hospital and by Silver Bow General Hospital.	St. James Community Hospital, Butte
3.	Cases of prostate, colon, and rectal cancers by county of residence for Broadwater, Jefferson, and Lewis and Clark Counties.	Dr. Stan Freni, Special Studies Branch, Centers for Disease Control, Atlanta, Georgia
4.	Number of patients by year, by primary site, by residence at diagnosis (for Broadwater, Jefferson, and Lewis and Clark Counties).	Dr. D. H. Hiesterman, Helena
5.	Number of patients and type of tumor for Billings and Yellowstone County, 1981-1983.	Dr. Neel Hammond, Billings
6.	State summary and survival figures, cancer incidence reported by NRCC.	Dr. Fred Deigert, NRCC, Billings
7.	Total number of patients from Yellowstone County by year and by site.	Lois Seiffert, Billings Deaconess Hospital, Billings
8.	Report on respiratory cancers by sex, by year of diagnosis, and by age group.	Richard Chiotti, Health Planning and Resource Development Bureau, State Dept. of Health & Env. Sciences, Helena
9.	Statistics for nine counties: total number of cancer patients, total number of patients with radiation therapy, 1981-1983.	Jerry Reeves, Montana Health Systems Agency, Helena
10.	Cancer incidence in Missoula County.	Dan Moe, Missoula City-County Health Dept., Missoula
11.	Cancer incidence in Richland County.	Dr. Donald Espelin, State Dept. of Health & Env. Sciences, Helena

SPECIAL STUDIES -- continued

	STUDY	REQUESTED BY
12.	Statistics for each county: number of cancer patients, total number of patients with radiation therapy, 1981 through August, 1984.	Wale Ogunwu, Montana Health Systems Agency, Helena
13.	Incidence by primary site for Broadwater, Jefferson, and Lewis and Clark Counties.	St. Peter's Community Hospital, Helena
14.	Incidence by primary site for Cascade County.	Montana Deaconess Hospital, Great Falls
15.	Occurrence of cancer in Indian children by year of diagnosis and county of residence.	Dr. John Opitz, Shodair Hospital, Helena
16.	Lung and prostate cancers reported for each county, alive and dead.	Suzanne Larson, Environmental Health Associates, Oakland, California
17.	Statewide cancer incidence per primary site.	Steve Shirley, Independent Record, Helena
18.	Incidence per county, per year, incidence rate, number of patients who received radiation therapy.	Verle Addy, Montana Health Systems Agency, Helena
19.	Number of cases per county per year.	Jeri Pullum, Montana Standard, Butte

DISTRIBUTION OF 10 MOST FREQUENT SITES
IN MONTANA
1979-1982

Site	Number of Cases	% of Total Cases
Lung	1,093	14%
Female Breast	953	12%
Prostate	924	12%
Colon	663	9%
Bladder	411	5%
Rectum	306	4%
Corpus Uteri	297	4%
Cervix In Situ	286	4%
Unknown Primary	258	3%
Pancreas	218	3%

RANKING OF FIVE MOST COMMON SITES[1] OF CANCER IN MONTANA BY COUNTY BY NUMBER OF CASES — AND INCIDENCE PER 100,000 — 1979-1982

COUNTY	LUNG		FEMALE BREAST***		PROSTATE***		COLON		BLADDER		TOTAL SITES	
	#	AAI	#	AAI	#	AAI	#	AAI	#	AAI	#	AAI
Beaverhead	21	61.4	5	28.3 14.2	11	64.2 29.1	11	32.2	7	19.4	109	301.9
Big Horn	24	68.4	6	29.8 16.2	9	51.9 24.9	6	16.7	1	3.1	82	223.5
Blaine	5	17.7	8	59.8 29.4	7	41.9 19.3	5	17.7	4	12.4	54	188.1
Broadwater	5	36.0	5	81.5 37.7	7	77.6 39.8	2	14.0	2	15.5	45	303.1
Carbon	20	40.5	10	36.2 18.8	8	34.1 15.2	7	11.8	4	10.6	90	181.0
Carter	1	8.4	2	57.4 27.0	1	20.2 10.3	2	16.8	1	6.2	15	156.4
Cascade	59	19.2	55	33.4 17.8	52	38.6 16.4	24	7.5	24	7.3	427	134.1
Chouteau	10	32.8	6	41.8 21.6	4	27.0 12.6	2	6.9	2	7.7	46	155.5
Custer	31	48.8	25	75.5 40.9	21	71.8 30.9	13	20.8	8	11.5	190	301.7
Daniels	1	8.8	5	83.3 41.6	7	90.1 43.9	1	5.9	2	8.5	27	171.1
Dawson	14	29.7	7	30.3 16.0	13	67.7 28.5	10	22.8	7	16.0	97	215.1
Deer Lodge	30	43.2	13	36.2 20.2	22	71.2 30.9	17	25.5	10	14.7	162	253.0
Fallon	2	13.0	4	40.9 23.3	2	27.2 13.5	5	35.0	2	12.6	26	175.6
Fergus	25	36.5	24	69.2 36.1	27	70.6 30.3	17	25.0	13	16.7	208	290.3
Flathead	54	25.9	42	40.9 20.9	62	65.2 29.8	23	11.0	26	12.7	357	172.4
Gallatin	27	22.1	31	47.1 25.2	36	65.1 28.4	25	18.5	11	7.6	230	174.5
Garfield	3	35.7	2	56.4 31.1	2	52.7 24.4	2	17.9	1	13.9	17	216.0
Glacier	10	26.2	8	36.4 20.3	7	42.8 18.7	8	19.2	4	9.4	64	160.8
Golden Valley	1	11.6	1	44.4 20.0	-	- -	3	56.7	-	-	11	217.5
Granite	7	62.8	7	77.5 38.7	6	72.0 39.4	6	42.8	1	5.9	41	293.3
Hill	18	26.7	20	55.9 30.5	12	39.3 17.6	15	21.3	7	8.3	135	196.7
Jefferson	9	38.8	9	71.8 35.0	8	74.4 33.8	6	27.1	5	21.0	75	299.0
Judith Basin	3	19.2	1	11.4 5.6	3	37.3 19.4	3	24.5	3	23.8	21	153.9
Lake	39	42.2	20	47.5 24.7	22	47.8 21.7	15	14.8	12	13.1	217	244.5
Lewis & Clark	81	50.2	76	87.2 47.5	55	80.9 33.1	58	34.4	20	12.0	523	316.3
Liberty	3	24.8	-	- -	1	13.2 8.2	3	32.0	4	37.4	17	161.2
Lincoln	29	47.6	22	70.7 35.6	18	66.5 30.9	14	22.8	7	10.5	178	286.4
Madison	4	12.0	2	12.8 6.5	8	56.6 21.5	3	9.2	3	8.4	44	146.6

COUNTY	LUNG		FEMALE BREAST***		PROSTATE***		COLON		BLADDER		TOTAL SITES	
	#	AAI	#	AAI	#	AAI	#	AAI	#	AAI	#	AAI
McCone	1	7.1	5	91.0 42.0	2	37.9 18.9	-	-	-	-	17	158.4
Meagher	6	62.7	4	96.7 44.5	2	59.7 20.3	4	39.3	2	18.5	37	371.2
Mineral	9	67.2	6	92.1 42.9	5	82.1 38.6	4	30.8	2	12.8	60	437.6
Missoula	92	38.5	101	73.7 39.6	69	67.6 28.5	71	29.1	50	20.6	751	290.5
Musselshell	6	21.0	14	117.3 61.5	9	71.0 31.8	3	11.1	4	22.2	55	227.1
Park	26	38.9	19	55.6 29.5	24	75.7 32.4	12	16.9	14	21.0	167	256.3
Petroleum	1	23.9	1	60.8 23.9	1	157.2 78.6	-	-	-	-	9	309.1
Phillips	8	34.9	10	95.3 46.6	7	53.6 27.8	4	15.3	3	9.8	54	224.4
Pondera	15	45.9	7	36.4 19.8	11	67.8 31.5	7	20.0	-	-	78	237.8
Powder River	-	-	1	21.1 9.0	3	53.6 24.9	6	60.4	-	-	22	205.0
Powell	13	42.2	13	79.2 41.1	18	128.1 57.1	7	23.4	3	11.0	95	311.0
Prairie	1	7.3	2	66.0 36.6	3	70.2 25.8	5	45.7	-	-	23	244.3
Ravalli	40	37.9	25	45.7 23.7	48	93.2 39.9	21	17.8	21	18.7	298	273.2
Richland	21	44.9	10	44.2 22.3	15	66.7 28.9	10	20.5	5	9.7	116	241.8
Roosevelt	15	38.6	14	63.1 32.4	11	55.7 22.7	5	12.4	1	1.2	99	229.9
Rosebud	8	26.8	13	83.2 39.4	4	40.0 18.3	3	11.8	2	8.3	61	203.1
Sanders	17	39.5	5	26.3 12.8	14	61.9 31.5	13	32.0	8	20.9	102	247.4
Sheridan	7	28.1	12	68.9 36.0	10	69.1 30.1	3	10.7	4	12.6	54	179.8
Silver Bow	74	37.0	66	61.0 33.8	70	78.5 31.5	69	33.8	40	18.8	555	281.6
Stillwater	11	40.3	7	41.8 22.5	7	39.8 19.2	1	2.9	-	-	56	187.6
Sweet Grass	4	21.4	5	52.2 26.3	7	52.7 23.9	4	16.5	1	4.6	45	230.0
Teton	6	15.8	11	68.7 35.7	5	33.2 14.6	6	17.3	5	14.0	60	185.4
Toole	4	17.4	6	46.4 25.2	6	49.0 22.3	2	7.9	2	6.1	30	121.5
Treasure	2	48.2	2	85.8 38.9	1	93.0 11.6	1	11.6	-	-	13	251.6
Valley	11	25.0	15	69.7 35.0	10	45.8 20.4	7	14.7	4	8.8	92	205.0
Wheatland	4	29.3	5	85.1 41.7	3	45.5 21.1	4	33.4	2	8.4	33	259.9
Wibaux	4	59.1	-	- -	2	48.3 27.0	-	-	-	-	11	166.5
Yellowstone	146	36.8	136	60.6 33.0	120	72.3 30.0	70	17.6	37	9.2	946	232.3
TOTAL STATE[2]	1,088	34.1	931	55.5 29.2	918	62.3 27.3	648	19.7	401	12.1	7,447	228.5

AAI — AGE-ADJUSTED INCIDENCE
*** — SEX SPECIFIC INCIDENCE
1 — EXCLUDES CARCINOMA IN-SITU OF CERVIX
2 — INCLUDES DATA FOR UNKNOWN COUNTY OF RESIDENCE

DATA AND DEFINITIONS

Total Sites (7,361) exclude cancer in-situ of the cervix and non-melanoma of the skin.

The survival curves depicting end results by stage of disease are observed (crude) survival rates. These rates are calculated according to the actuarial method of Berkson and Gage. This method reflects mortality not only from cancer but also deaths due to all other cases. When the number of patients surviving beyond any year is less than ten, or where the standard error rate becomes greater than 10.0%, the curve is terminated. The expected (normal) life curve has been calculated using the exact age and sex distribution of the particular group of cancer patients, calculating their survival as if they did not have cancer.

The frequency by sex graph gives the percentage of men and women developing a specific cancer.

On the age at diagnosis graph, each point represents the percentage of cancer victims for each site who were diagnosed in the previous 10-year age group.

The stage of disease at diagnosis graph indicates the percentage of cancers diagnosed at each stage. On these graphs, in-situ and localized are combined. Except for cervix, the percentage of in-situ is less than 1.0%. The cervix is presented as two separate graphic displays, one for cervix, invasive, and one for cervix, in-situ.

The stage of disease at diagnosis is based on all available data, i.e., examination, x-rays, operations, pathology reports, etc.

The figures in this report represent only Montana residents.

Stage Definitions:

In-situ:
A tumor that fulfills all of the criteria for malignancy except invasion.

Localized:
A tumor that appears to be confined entirely to the organ of origin.

Regional:
A tumor that has extended beyond the limits of the organ into (1) the surrounding organs or tissues by direct extension, (2) regional lymph nodes by metastasis, or (3) a combination of (1) and (2), but appears to have spread no further.

Distant or Remote:
A tumor that has spread to parts of the body remote from the primary tumor.

Unknown or Unstaged:
There is insufficient information to allow for accurate staging.

The stage of treatment (first course) depicts treatment combinations for each site. Each combination is printed as a percentage of the total cases for that group.

On the following pages are graphics for each site of cancer, utilizing the above definitions.

TOTAL SITES
7361 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	7361	42%	9%	6%	1%	11%	4%	2%	4%	1%	1%	2%	1%	0%	0%	0%	17%
LOCALIZED	2583	65%	7%	1%	0%	14%	2%	2%	1%	0%	0%	1%	1%	0%	0%	0%	6%
REGIONAL	1613	48%	8%	3%	0%	17%	8%	1%	3%	0%	0%	3%	1%	0%	0%	0%	7%
DISTANT	1498	12%	11%	15%	3%	6%	7%	3%	9%	2%	2%	2%	1%	1%	1%	0%	22%
UNKNOWN	102	77%	2%	0%	0%	5%	3%	0%	0%	0%	0%	1%	0%	0%	0%	0%	12%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

143- TO 145- MOUTH
54 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	54	43%	11%	2%	0%	26%	6%	0%	2%	0%	0%	2%	0%	0%	0%	0%	9%
LOCALIZED	30	63%	20%	0%	0%	17%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
REGIONAL	12	25%	0%	8%	0%	50%	8%	0%	0%	0%	0%	8%	0%	0%	0%	0%	0%
DISTANT	4	0%	0%	0%	0%	25%	25%	0%	25%	0%	0%	0%	0%	0%	0%	0%	25%
UNKNOWN	1	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	100%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

146- TO 9- PHARYNX
50 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	50	10%	38%	2%	0%	26%	2%	0%	10%	0%	0%	2%	0%	0%	0%	0%	10%
LOCALIZED	12	8%	58%	0%	0%	25%	0%	0%	8%	0%	0%	0%	0%	0%	0%	0%	0%
REGIONAL	24	8%	33%	4%	0%	33%	4%	0%	13%	0%	0%	4%	0%	0%	0%	0%	0%
DISTANT	4	0%	0%	0%	0%	50%	0%	0%	25%	0%	0%	0%	0%	0%	0%	0%	25%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

150- ESOPHAGUS
62 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	62	18%	26%	5%	2%	15%	0%	0%	2%	0%	0%	0%	0%	0%	0%	0%	34%
LOCALIZED	15	13%	53%	0%	0%	7%	0%	0%	7%	0%	0%	0%	0%	0%	0%	0%	20%
REGIONAL	18	39%	17%	0%	0%	28%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	17%
DISTANT	10	0%	10%	10%	10%	30%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	20%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R RADIATION C = CHEMOTHERAPY H HORMONAL, IMM. OR OTHER)

151- STOMACH
138 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	138	48%	3%	9%	0%	1%	4%	1%	2%	0%	1%	1%	0%	1%	0%	1%	29%
LOCALIZED	20	80%	0%	0%	0%	0%	0%	5%	5%	0%	0%	0%	0%	0%	0%	0%	10%
REGIONAL	58	60%	3%	12%	0%	2%	5%	0%	2%	0%	0%	3%	0%	0%	0%	2%	10%
DISTANT	26	31%	8%	19%	0%	0%	4%	0%	4%	0%	4%	0%	0%	4%	0%	0%	27%
UNKNOWN	1	100%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

153- COLON

663 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	663	78%	0%	2%	0%	2%	8%	0%	1%	0%	0%	1%	0%	0%	0%	0%	9%
LOCALIZED	196	98%	0%	0%	0%	0%	1%	0%	0%	0%	0%	1%	0%	0%	0%	0%	1%
REGIONAL	298	84%	0%	1%	0%	3%	8%	0%	0%	0%	0%	0%	0%	0%	0%	0%	3%
DISTANT	95	41%	0%	8%	0%	0%	25%	2%	5%	0%	0%	1%	0%	1%	0%	0%	16%
UNKNOWN	13	85%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	15%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

154- RECTUM
306 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	306	60%	4%	1%	0%	18%	4%	0%	1%	0%	0%	2%	0%	0%	0%	0%	10%
LOCALIZED	92	84%	1%	0%	0%	11%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	3%
REGIONAL	117	62%	2%	0%	0%	27%	3%	0%	2%	0%	0%	2%	0%	0%	0%	1%	3%
DISTANT	55	33%	9%	7%	0%	15%	13%	0%	4%	0%	0%	7%	0%	0%	0%	0%	13%
UNKNOWN	4	50%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	50%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

'57- PANCREAS
218 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	218	15%	4%	7%	0%	2%	3%	0%	7%	0%	0%	6%	0%	0%	0%	0%	56%
LOCALIZED	14	29%	7%	0%	0%	0%	0%	0%	0%	0%	0%	21%	0%	0%	0%	7%	36%
REGIONAL	88	19%	3%	10%	0%	5%	5%	0%	11%	0%	0%	8%	0%	0%	0%	0%	39%
DISTANT	39	8%	10%	5%	0%	3%	3%	0%	3%	0%	0%	0%	0%	0%	0%	0%	69%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

161- LARYNX
116 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	116	31%	30%	0%	0%	20%	0%	0%	0%	0%	0%	1%	0%	0%	0%	0%	18%
LOCALIZED	63	30%	40%	0%	0%	13%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	17%
REGIONAL	21	38%	14%	0%	0%	48%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	3	0%	0%	0%	0%	33%	0%	0%	0%	0%	0%	33%	0%	0%	0%	0%	33%
UNKNOWN	10	40%	10%	0%	0%	30%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	20%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

16[illegible] LUNG
1093 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	1093	16%	24%	9%	0%	6%	1%	0%	12%	2%	0%	2%	0%	0%	1%	0%	25%
LOCALIZED	173	58%	13%	4%	0%	1%	0%	1%	6%	1%	0%	3%	0%	1%	0%	1%	13%
REGIONAL	195	17%	30%	4%	0%	18%	1%	0%	14%	1%	0%	3%	0%	1%	0%	0%	12%
DISTANT	412	5%	27%	13%	0%	8%	1%	0%	18%	2%	1%	2%	0%	0%	2%	0%	21%
UNKNOWN	1	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	100%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

169- ACUTE LEUKEMIA
79 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	79	0%	1%	37%	3%	0%	1%	0%	16%	0%	10%	1%	0%	0%	3%	0%	28%
LOCALIZED	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
REGIONAL	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	79	0%	1%	37%	3%	0%	1%	0%	16%	0%	10%	1%	0%	0%	3%	0%	28%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

169- CHRONIC LEUKEMIA
56 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	56	2%	0%	30%	0%	0%	0%	0%	2%	0%	5%	0%	0%	2%	0%	0%	59%
LOCALIZED	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
REGIONAL	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	56	2%	0%	30%	0%	0%	0%	0%	2%	0%	5%	0%	0%	2%	0%	0%	59%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

169- MULTIPLE MYELOMA
66 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	66	0%	2%	42%	0%	0%	2%	0%	8%	0%	11%	0%	0%	0%	5%	2%	30%
LOCALIZED	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
REGIONAL	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	62	0%	2%	44%	0%	0%	2%	0%	8%	0%	11%	0%	0%	0%	5%	2%	27%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

172- MELANOMA SKIN
104 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	104	79%	1%	1%	0%	4%	4%	1%	0%	0%	0%	0%	0%	2%	0%	0%	9%
LOCALIZED	76	88%	1%	0%	0%	3%	4%	0%	0%	0%	0%	0%	0%	1%	0%	0%	3%
REGIONAL	7	71%	0%	0%	0%	14%	0%	14%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	3	33%	0%	0%	0%	0%	33%	0%	0%	0%	0%	0%	0%	0%	0%	0%	33%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

174- BREAST FEMALE
953 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	953	66%	2%	2%	0%	10%	9%	1%	1%	0%	0%	3%	1%	0%	0%	0%	5%
LOCALIZED	429	86%	1%	0%	0%	9%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	2%
REGIONAL	341	52%	1%	1%	0%	13%	19%	2%	1%	0%	0%	6%	1%	1%	0%	1%	3%
DISTANT	69	14%	9%	14%	1%	7%	12%	7%	10%	1%	0%	9%	1%	0%	3%	0%	10%
UNKNOWN	20	95%	0%	0%	0%	0%	5%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

+180- CERVIX INSITU
286 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	286	94%	0%	0%	0%	1%	0%	1%	0%	0%	0%	0%	0%	0%	0%	0%	5%
LOCALIZED	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
REGIONAL	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
UNKNOWN	286	94%	0%	0%	0%	1%	0%	1%	0%	0%	0%	0%	0%	0%	0%	0%	5%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

180- CERVIX UTERI
112 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	112	29%	37%	0%	0%	18%	0%	0%	2%	2%	0%	1%	1%	0%	0%	0%	11%
LOCALIZED	52	50%	25%	0%	0%	19%	0%	0%	2%	0%	0%	0%	2%	0%	0%	0%	2%
REGIONAL	26	8%	50%	0%	0%	31%	0%	0%	0%	0%	0%	4%	0%	0%	0%	0%	8%
DISTANT	12	0%	58%	0%	0%	8%	0%	0%	8%	8%	0%	0%	0%	0%	0%	0%	17%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

182- CORPUS UTERI
297 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	297	46%	7%	1%	1%	33%	2%	1%	0%	0%	0%	1%	1%	0%	0%	0%	7%
LOCALIZED	192	56%	5%	0%	0%	34%	1%	1%	0%	0%	0%	1%	1%	0%	0%	0%	2%
REGIONAL	39	26%	10%	0%	0%	54%	3%	0%	0%	0%	0%	0%	5%	0%	0%	0%	3%
DISTANT	15	27%	7%	13%	7%	13%	27%	0%	0%	0%	0%	0%	0%	0%	0%	0%	7%
UNKNOWN	9	89%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	11%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

183- OVARY-TUBE-LIGAMENT

161 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	161	30%	0%	13%	0%	5%	39%	0%	1%	0%	1%	1%	0%	2%	0%	0%	8%
LOCALIZED	31	61%	0%	0%	0%	10%	19%	0%	0%	0%	0%	0%	0%	3%	0%	0%	6%
REGIONAL	15	20%	0%	7%	0%	0%	60%	0%	7%	0%	0%	7%	0%	0%	0%	0%	0%
DISTANT	86	23%	0%	13%	0%	6%	45%	0%	0%	0%	0%	1%	0%	3%	0%	0%	8%
UNKNOWN	1	100%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

184- FEMALE GENITAL
50 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	50	62%	10%	0%	0%	6%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	20%
LOCALIZED	19	63%	5%	0%	0%	16%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	16%
REGIONAL	8	50%	25%	0%	0%	0%	13%	0%	0%	0%	0%	0%	0%	0%	0%	0%	13%
DISTANT	2	0%	50%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	50%
UNKNOWN	14	79%	7%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	14%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

185- PROSTATE
924 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	924	35%	9%	0%	8%	17%	0%	11%	0%	3%	0%	0%	3%	0%	0%	0%	13%
LOCALIZED	421	48%	8%	0%	1%	24%	0%	7%	0%	0%	0%	0%	3%	0%	0%	0%	8%
REGIONAL	81	22%	16%	0%	0%	38%	0%	11%	0%	0%	0%	1%	7%	0%	0%	0%	4%
DISTANT	167	13%	4%	1%	26%	7%	0%	22%	1%	12%	1%	1%	4%	1%	0%	0%	8%
UNKNOWN	3	100%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

18[illegible]- TESTIS
60 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	60	33%	0%	0%	0%	42%	18%	0%	0%	0%	0%	3%	0%	0%	0%	0%	3%
LOCALIZED	31	48%	0%	0%	0%	42%	6%	0%	0%	0%	0%	0%	0%	0%	0%	0%	3%
REGIONAL	11	9%	0%	0%	0%	64%	18%	0%	0%	0%	0%	9%	0%	0%	0%	0%	0%
DISTANT	11	18%	0%	0%	0%	27%	36%	0%	0%	0%	0%	9%	0%	0%	0%	0%	9%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

188- BLADDER
411 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	411	70%	2%	1%	0%	14%	3%	0%	0%	0%	0%	1%	0%	0%	0%	0%	8%
LOCALIZED	278	77%	2%	0%	0%	12%	4%	1%	0%	0%	0%	0%	0%	0%	0%	0%	5%
REGIONAL	43	51%	5%	0%	0%	40%	0%	0%	0%	0%	0%	2%	0%	0%	0%	0%	2%
DISTANT	12	8%	17%	8%	0%	17%	0%	0%	8%	8%	0%	17%	0%	0%	0%	0%	17%
UNKNOWN	10	70%	0%	0%	0%	0%	20%	0%	0%	0%	0%	0%	0%	0%	0%	0%	10%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

1890 KIDNEY
138 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	138	63%	3%	1%	1%	4%	4%	4%	0%	0%	0%	2%	2%	1%	0%	0%	14%
LOCALIZED	43	93%	0%	0%	0%	0%	5%	0%	0%	0%	0%	0%	0%	0%	0%	0%	2%
REGIONAL	41	78%	0%	0%	2%	5%	5%	5%	0%	0%	0%	0%	0%	2%	0%	0%	2%
DISTANT	34	24%	3%	0%	3%	9%	3%	12%	0%	0%	0%	9%	9%	3%	0%	0%	26%
UNKNOWN	1	100%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

191'2- BRAIN & CNS
190 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	190	21%	16%	1%	2%	25%	0%	4%	2%	3%	0%	8%	3%	0%	1%	1%	14%
LOCALIZED	149	19%	17%	0%	2%	29%	0%	5%	2%	1%	0%	10%	3%	0%	1%	1%	9%
REGIONAL	1	0%	100%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
UNKNOWN	1	100%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

193- THYROID
87 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	87	70%	1%	0%	0%	11%	2%	2%	1%	0%	0%	0%	2%	0%	0%	0%	9%
LOCALIZED	45	84%	0%	0%	0%	2%	2%	2%	0%	0%	0%	0%	0%	0%	0%	0%	9%
REGIONAL	26	65%	0%	0%	0%	27%	4%	4%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	8	13%	13%	0%	0%	25%	0%	0%	13%	0%	0%	0%	25%	0%	0%	0%	13%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

196- HODGKINS
63 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	63	2%	24%	16%	0%	14%	5%	0%	8%	0%	3%	2%	0%	0%	2%	2%	24%
LOCALIZED	22	5%	41%	0%	0%	23%	5%	0%	0%	0%	0%	0%	0%	0%	0%	5%	23%
REGIONAL	12	0%	33%	17%	0%	25%	0%	0%	17%	0%	0%	0%	0%	0%	8%	0%	0%
DISTANT	14	0%	0%	43%	0%	0%	14%	0%	7%	0%	7%	7%	0%	0%	0%	0%	21%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

196- LYMPH. NON-HODGKINS
162 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	162	8%	13%	33%	1%	2%	7%	0%	7%	1%	6%	1%	1%	1%	2%	0%	18%
LOCALIZED	26	12%	35%	27%	0%	4%	4%	0%	4%	0%	4%	4%	0%	0%	0%	0%	8%
REGIONAL	22	5%	5%	41%	0%	0%	14%	0%	0%	0%	14%	0%	5%	0%	5%	0%	14%
DISTANT	64	8%	8%	39%	0%	3%	3%	0%	11%	2%	5%	2%	0%	2%	2%	0%	17%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

199- UNKNOWN PRIMARY
258 CASES







STAGE BY TREATMENT (FIRST COURSE) 1979 - 1982

	N OF CASES	S	R	C	H	SR	SC	SH	RC	RH	CH	SRC	SRH	SCH	RCH	SRCH	NONE
ALL STAGES	258	9%	14%	16%	1%	4%	2%	0%	6%	2%	1%	2%	1%	0%	0%	0%	43%
LOCALIZED	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
REGIONAL	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DISTANT	59	7%	14%	17%	2%	5%	2%	0%	14%	5%	2%	2%	0%	0%	2%	0%	31%
UNKNOWN	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

(S = SURGERY R = RADIATION C = CHEMOTHERAPY H = HORMONAL, IMM. OR OTHER)

2,000 copies of this public document were published at an estimated cost of $1.50 per copy, for a total cost of $3,000.00, which includes $2,500.00 for printing and $500.00 for distribution.